CROOZ
16.5.2023 05:01:27 CEST | Business Wire | Press release
CROOZ, Inc. (listed on the Tokyo Stock Exchange Standard Market: 2138; head office: Shibuya-ku, Tokyo; the President and CEO: Koji Obuchi; hereinafter "CROOZ") announced that it has officially launched PROJECT XENO, an NFT game developed by the company.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230515005017/en/
XENO_TOP (Graphic: Business Wire)
About PROJECT XENO
PROJECT XENO is a blockchain game operated by EPOCH FACTORY and developed by CROOZ, a listed Japanese company. The full-scale tactical battle NFT game combines GameFi, e-Sports, and Fun. PROJECT XENO is available globally and can be played on smartphones and PCs.
PROJECT XENO has the following features.
Feature (1) Collaboration with celebrities such as Floyd Mayweather JR
The game has appointed some ambassadors to reach users around the world; popular YouTuber Hikaru as an ambassador in Japan, along with eight-division boxing world champion Manny Pacquiao and Fumiya, "the most famous Japanese in the Philippines," as ambassadors in Southeast Asia. In addition, NFTs collaborated with former five-division boxing world champion Floyd Mayweather Jr. and others are also available.
Feature (2) Developed by a listed Japanese company
PROJECT XENO is developed and operated by a listed company that has released many hit smartphone games in the Japanese market and is able to provide high-quality games and stable operations.
Feature (3) “Web 2.5” specifications that also enable users without NFT to play
PROJECT XENO is a free-to-play game, meaning that it can still be played by users who do not own NFT. Furthermore, the game supports in-game purchases, allowing users to play the game in exactly the same way as NFT holders. The only difference with NFT holders is the presence or absence of the Earn feature. There are no discrepancies in character strength, etc., allowing PROJECT XENO to be played like any other social game. If social games are Web 2.0 and GameFi games are Web 3.0, then PROJECT XENO can be considered a Web 2.5 game.
About GXE tokens
GXE is a token distributed on PROJECT XENO. GXE is listed on MEXC Global, LBank, BKEX, Bittrex Global, and Gate.io. On May 16, 2023 (Japan time), it was also listed on BITPoint, a crypto asset exchange of the SBI Group based in Tokyo, Japan. BITPoint has been approved as a crypto asset exchange operator by the Japanese Financial Services Agency.
The latest information on PROJECT XENO
For more information on PROJECT XENO, visit the website.
Up-to-date information is also available on Twitter.
- PROJECT XENO: http://project-xeno.com/
- PROJECT XENO Official Twitter: https://twitter.com/PROJECTXENO_GLB
About CROOZ, Inc.
With the fashion shopping site "SHOPLIST.com by CROOZ" at its core, CROOZ, Inc. develops a wide range of Internet services in the entertainment domain, including shopping and games, always in step with the changing times.
https://crooz.co.jp
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230515005017/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom